HER 2/NEU oncoprotein: a biomacker in human prostate cancer

To determine the frequencies of HER-2/neu overexpression in prostate adenocarcinoma. A retrospective study of 50 patients suffering from prostate adenocarcinoma. BMSI, Jinnah Post Graduate Medical Centre Karachi 1999-2001. Fifty patients between the ages of 50-80 years were selected during period 1990-2001 having prostate carcinoma. Maximum numbers of tumour among total cases were in age group ranging from 51-60 years i.e.13 tumours [26% of total cases]. Frequency of HER/2neu expression was found to be 12%. All the positive cases were poorly differentiated with Gleason score 8-10. HER-2/neu overexpression was present in 12% of prostatic adenocarcinoma cases. Specific therapeutic targeting of these neoplasms may be accomplished with [Herceptin], which may reveal a new treatment option

Prostatic cancer - A retrospective study of 50 patients

This Objective of this study was to see histologic typing of prostate cancer and its relation to patient's age, as no curative therapy exists for the advanced stages. This is a retrospective study of 50 patients suffering from prostatic adenocarcinoma and admitted at Basic Medical Sciences Institute, Jinnah Postgraduate Medical Center Karachi. A total of fifty patients between ages of 50-80 years diagnosed during the period of 1990-2001 suffering from prostate cancer were included in this study. The result showed that maximum number of tumours were in age group ranging from 61-70 years, [58% of total cases]. Sixteen were [32%] well-differentiated tumours, twenty-eight [56%], moderately differentiated tumours and six [12%] were labelled as undifferentiated tumours. It was concluded that the majority of tumors were moderately differentiated tumours. Early diagnosis is useful for patients; because high grade tumours have bad prognostic markers